ClinicalTrials.gg
RecruitingNCT07475351Updated Mar 23, 2026

Comparison of Bone-patellar Tendon-bone and Patellar Tendon-bone Grafts in ACL Reconstruction

An interventional study of Bone-Patellar tendon-Bone and Patellar tendon-Bone in Anterior Cruciate Ligament (ACL) Reconstruction and Anterior Cruciate Ligament Injury, sponsored by Universidad de Granada. Recruiting at 1 site in Spain. Open to participants aged 12 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-03-23.

Sponsored by Universidad de Granada · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
12 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Anterior Cruciate Ligament Injuries with a site in Spain — 6 open to participants now, 7 under way, none of them phase 3. Anterior Cruciate Ligament Injuries · Spain.

Planned enrollment
2nd of 10
110 · median 44
Started
2026
with 2 others
No phase
10 of 12
4 open now
Registered
11th of 12
by date
Lead sponsor
2 of 12
Universidad de Granada

Among the 12 studies in Anterior Cruciate Ligament Injuries with a site in Spain, this one is the 2nd largest by planned enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2026, is one of 10 with no phase, and was the 11th registered.

Anterior Cruciate Ligament Injuries

627 studies on the registry are indexed under Anterior Cruciate Ligament Injuries; 193 are open to participants now.

Browse Anterior Cruciate Ligament Injuries studies →

Open to participants now

6 of the 12 studies in Anterior Cruciate Ligament Injuries with a site in Spain are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 122 Anterior Cruciate Ligament Injuries studies recruiting now, 27 (22%) set no upper age limit and 92 (75%) stop at 75 or younger; 46 take children under 18; 21 take healthy volunteers.

This study: 12 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Anterior Cruciate Ligament Injuries with a site in Spain, or all of them as a file.
02

Study summary

The purpose of this randomized study is to compare donor site morbidity and clinical and functional outcomes of both surgery techniques (bone-patellar tendon-bone (BPTB) graft versus bone-patellar tendon without patellar bone plug (PT) graft) for anterior cruciate ligament reconstruction (ACLR) in athletes. The main questions it aims to answer are:

  • Does PT graft reduce donor site morbidity compared to the standard BPTB graft?
  • Does PT technique provide clinical and functional results comparable to the BPTB technique? Researchers will compare the incidence of complications and clinical and functional outcomes between the BPTB and PT grafts groups.

Patients will:

  • Undergo ACLR surgical intervention using one of the two assigned techniques (BPTB or PT)
  • Follow a two-year assessment program, including visits at three, eight, 12 and 24 months after surgery.
Read the detailed description

Anterior cruciate ligament (ACL) rupture is the most prevalent type of knee ligament injury, representing approximately 50% of all reported knee injuries. This injury has a particularly high impact on most athletes due to the demands of pivoting, jumping and cutting movements required during play. In addition, its consequences include a prolonged recovery period, the risk of reinjury and complications arising from ACL insufficiency, such as knee instability, meniscal tears or osteoarthritis. Given that the primary indicator of successful treatment is the athlete's ability to return to competitive levels, surgical reconstruction of the ACL (ACLR) has become the standard treatment. However, the choice of the optimal graft for ACLR remains controversial. For many authors, bone-patellar tendon-bone (BPTB) graft is considered gold-standard option due to optimal biomechanical properties and low reinjury rate. However, BPTB is usually associated with donor site morbidity, specifically related to kneeling, dysesthesia and anterior knee pain.

Given the disadvantages of the BPTB graft, an ACLR based on a bone-patellar tendon graft may be a viable alternative. This technique utilizes an autograft composed of the central third of the patellar tendon and a tibial tubercle bone plug without inclusion of the patellar bone plug, called bone-patellar tendon (BPT). Previous studies have demonstrated lower rates of anterior knee pain in BPT compared to BPTB. However, there is a lack of evidence regarding objective and specific donor site morbidity assessment for both techniques.

The main hipothesis of this study is that BPT has similar clinical an functional recovery compared to BPTB with lower rates of anterior knee morbidity.

03

Conditions studied

  • Anterior Cruciate Ligament (ACL) Reconstruction
  • Anterior Cruciate Ligament Injury

Keywords

  • ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION
  • BONE PATELLAR TENDON BONE
  • PATELLAR TENDON
04

Who can participate

Ages eligible
12 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Time for injury to surgery of less than six months.
  • Active athletes (federated or recreational)
  • Patellar tendon length > 42mm measured by MRI.
  • Age between 12 and 40 years old
  • Genders eligible for Study: both

Exclusion criteria

Exclusion Criteria:

  • Previous surgery or history of ligamentous knee injuries.
  • Concomitant knee ligament injury
  • Major meniscal injury (more than 50% of the lateral or medial meniscus)
  • Chondral injury greater than Outerbridge Grade I-II
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
110 participants (estimated)

Study arms

  • Active comparator
    Patellar tendon - Bone (PT)

    Procedure: Patellar tendon-Bone

  • Active comparator
    Bone - Patellar tendon - Bone (BPTB)

    Procedure: Bone-Patellar tendon-Bone

Interventions

  • ProcedureBone-Patellar tendon-Bone

    After an arthroscopic examination via an anterolateral viewing portal to confirm the ACL injury, two additional portals will be established: an accessory medial portal slightly above the joint line (approximately 2cm from the medial border of the patellar tendon) and a high anteromedial portal. Once associated lesions are addressed, the graft is harvested through a 6cm longitudinal midline incision. Following paratenon dissection, the patellar tendon dimensions are measured: * Minimum length: 42mm * Width-based harvesting: if the tendon width is \<30mm, a graft consisting of one-third of the total width is harvested. If the width exceeds 30mm, a 10mm wide graft is obtained. * Bone plugs: patellar and tibial bone plugs (10x20x8mm) are harvested. While the graft is prepared, anatomic tunnels are created. The graft is secured with MectaScrew (MEDACTA) interference screws. Once fixed, an extra-articular tenodesis is performed using Arnold \& Coker technique.

  • ProcedurePatellar tendon-Bone

    After an arthroscopic examination via an anterolateral viewing portal to confirm the ACL injury, two additional portals will be established: an accessory medial portal slightly above the joint line (approximately 2cm from the medial border of the patellar tendon) and a high anteromedial portal. Once associated lesions are addressed, the graft is harvested through a 6cm longitudinal midline incision. Following paratenon dissection, the patellar tendon dimensions are measured: * Minimum length: 42mm * Width-based harvesting: if the tendon width is \<30mm, a graft consisting of one-third of the total width is harvested. If the width exceeds 30mm, a 10mm wide graft is obtained. * Bone plugs: a tibial bone plug (10x20x8mm) is harvested. While the graft is prepared, anatomic tunnels are created. The graft is secured with MectaScrew (MEDACTA) interference screws. Once fixed, an extra-articular tenodesis is performed using Arnold \& Coker technique.

    Also known as: Patellar tendon

06

What researchers measure

Primary outcomes

  1. Donor Site Morbidity

    Anterior Cruciate Ligament Donor-site Morbidity Questionnaire will be used to evaluate complications at the harvest site. Scores range from 0 to 100 points, where higher scores indicates better ouctome (absence of donor-site complications).

    Time frame: At 3, 8, 12 and 24 months after surgery

Secondary outcomes

  1. Function and activity level

    Lysholm-Tegner score will be used to report knee function and activity level. Scores range from 0 to 100 points, where 100 indicates a better outcome (knee function).

    Time frame: Baseline (Pre-intervention) and 3, 8, 12 and 24 months after surgery

  2. Subjective knee status

    International Knee Documentation Committee (IKDC) will be used to assess knee signs and symptoms. Total scores range from 0 to 100 points, where a higher score indicates a better outcome (absence of symptoms and maximum functional level).

    Time frame: Baseline (Pre-intervention) and 3, 8, 12 and 24 months after surgery

  3. Psychological readiness

    Anterior cruciate ligament - Return to Sport after Injury (ACL-RSI) Scale will be used to evaluate psychological readiness of patients to return to sport after ACL reconstruction. Scores range from 0 to 100 points, where a higher score indicates better outcome (full psychological readiness and confidence).

    Time frame: Baseline (Pre-intervention) and 3, 8, 12 and 24 months after surgery

  4. Joint Awareness

    Forgotten Joint Score (FJS) will be used to assessthe patient's ability to forget their affected joint during activities. Scores range from 0 to 100 points, where higher scores indicate a better outcome (patients "forget" the joint, representing a natural feel).

    Time frame: Baseline (Pre-intervention) and 3, 8, 12 and 24 months after surgery

  5. Patient-reported symptoms

    Cincinnati Knee Rating System will be used to ievaluate patient-reported symptoms. scores range from 0 to 100 points, where a higher score (100) indicates better outcome (excellent clinical result, no symptoms, and full return to sports).

    Time frame: Baseline (Pre-intervention) and 3, 8, 12 and 24 months after surgery

  6. Quadriceps strength

    Isokinetic test will be used to evaluate quadriceps peak torque and limb symmetry index. After a warm-up of 10 minutes, patients will perform 5 and 10 unilateral repetitions at 60 and 180º/s respectively, with one minute of rest between series.

    Time frame: Baseline (Pre-intervention) and 3, 8, 12 and 24 months after surgery

  7. Hamstrings strength

    Isokinetic test will be used to evaluate hamstrings peak torque and limb symmetry index. After a warm-up of 10 minutes, patients will perform 5 and 10 unilateral repetitions at 60 and 180º/s respectively, with one minute of rest between series.

    Time frame: Baseline (Pre-intervention) and 3, 8, 12 and 24 months after surgery

  8. Hamstring/Quadriceps ratio

    HQ ratio will be calculated with hamstring and quadriceps peak torque from isokinetic tests.

    Time frame: Baseline (Pre-intervention) and 3, 8, 12 and 24 months after surgery

  9. Functional Hop Test Battery

    A series of four hop tests will be performed to measure dynamic stability and neuromuscular control. Distance and limb symmetry index will be registered.

    Time frame: Baseline (Pre-intervention) and 8, 12 and 24 months after surgery

  10. Donor-site pain pressure threshold

    Pain pressure threshold measured via digital algometry will be used at the patellar tendon.

    Time frame: Baseline (Pre-intervention) and 3, 8, 12 and 24 months after surgery

  11. Quadriceps thickness

    An ultrasound system with a linear probe will be used to measure quadriceps thickness.

    Time frame: Baseline (Pre-intervention) and 3, 8, 12 and 24 months after surgery

  12. Patellar tendon morphology

    An ultrasound system with a linear probe will be used to measure patellar tendon thickness and cross-sectional area.

    Time frame: Baseline (Pre-intervention) and 3, 8, 12 and 24 months after surgery

  13. Anteroposterior knee stability

    A Lachmeter system will be used to evaluate anteroposterior knee stability

    Time frame: Baseline (Pre-intervention) and 3, 8, 12 and 24 months after surgery

  14. Knee stability

    A KIRA system will be used to evaluate anteroposterior and rotational knee stability

    Time frame: Baseline (Pre-intervention) and 3, 8, 12 and 24 months after surgery

  15. Height

    A tallimeter will be used to register height, expressed in meters (m).

    Time frame: Baseline (Pre-intervention) and 3, 8, 12 and 24 months after surgery

  16. Weight

    Bioelectrical impedance analysis (BIA) will be performed by using an Inbody 970 for measuring weight, expressed in kilograms (kg).

    Time frame: Baseline (Pre-intervention) and 3, 8, 12 and 24 months after surgery

  17. Body Mass Index (BMI)

    Bioelectrical impedance analysis (BIA) will be performed by using an Inbody 970 for measuring BMI, expressed in kg/m\^2.

    Time frame: Baseline (Pre-intervention) and 3, 8, 12 and 24 months after surgery

  18. Percentage of Body Fat

    Bioelectrical impedance analysis (BIA) will be performed by using an Inbody 970 for measuring PBF, expressed in %.

    Time frame: Baseline (Pre-intervention) and 3, 8, 12 and 24 months after surgery

  19. Skeletal Muscle Mass

    Bioelectrical impedance analysis (BIA) will be performed by using an Inbody 970 for measuring SMM, expressed in kg.

    Time frame: Baseline (Pre-intervention) and 3, 8, 12 and 24 months after surgery

07

Study locations

1 of 1 sites recruiting
  • Health Sciences Faculty, University of Granada
    Granada, Granada 18016, Spain
    Recruiting
    • Jose M Rodriguez-Delgado · Contactjosemariard@ugr.es · +34664807986
    • Manuel Arroyo-Morales · Principal investigator
    • Jose Luis Martin-Alguacil · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Mar 2027, 14 months after the start.

Of 279 non-industry interventional studies with no phase under Anterior Cruciate Ligament Injuries, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 70. This study's planned 14 months is below that.

Counting every sponsor, half of 288 studies reached it within 30 months; a quarter within 14 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2026
First posted
Mar 16, 2026
StartActual
Jan 1, 2026
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2028
Last update
Mar 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07475351
Responsible party
Jose M Rodriguez-Delgado (MsC, PT, Universidad de Granada) — Principal investigator
First posted
Mar 16, 2026
Start date
Jan 1, 2026
Primary completion
Mar 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
Mar 23, 2026

Study contacts

Jose M Rodriguez-Delgado
Contact
josemariard@ugr.es
+34664807986
Jose Luis Martin-Alguacil
Contact
joseluismartinalguacil@hotmail.com
+34666523667
Manuel Arroyo-Morales
study chair · Universidad de Granada

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion